Rachel Beckerman

3.1k total citations · 1 hit paper
45 papers, 2.4k citations indexed

About

Rachel Beckerman is a scholar working on Molecular Biology, Oncology and Hepatology. According to data from OpenAlex, Rachel Beckerman has authored 45 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Oncology and 11 papers in Hepatology. Recurrent topics in Rachel Beckerman's work include Hepatitis C virus research (9 papers), Liver Disease Diagnosis and Treatment (8 papers) and Cancer-related Molecular Pathways (7 papers). Rachel Beckerman is often cited by papers focused on Hepatitis C virus research (9 papers), Liver Disease Diagnosis and Treatment (8 papers) and Cancer-related Molecular Pathways (7 papers). Rachel Beckerman collaborates with scholars based in United States, United Kingdom and Germany. Rachel Beckerman's co-authors include Carol Prives, Zobair M. Younossi, Maria Stepanova, Linda Henry, Youssef Younossi, Sharon Hunt, Deirdre B Blissett, Robert Blissett, Andrei Racila and Oleg Laptenko and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Rachel Beckerman

43 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

2016 916 citations Zobair M. Younossi, Linda Henry et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rachel Beckerman United States	19	1.0k	1.0k	584	564	362	45	2.4k
Hironori Mitsuyoshi Japan	26	1.3k 1.2×	828 0.8×	596 1.0×	226 0.4×	225 0.6×	59	2.3k
Mitsuteru Kitade Japan	32	1.2k 1.1×	1.2k 1.2×	1.2k 2.0×	522 0.9×	527 1.5×	88	3.2k
Paraskevi A. Farazi United States	15	587 0.6×	1.3k 1.3×	585 1.0×	720 1.3×	589 1.6×	47	2.6k
Hong‐Yang Wang China	20	854 0.8×	1.3k 1.3×	922 1.6×	832 1.5×	734 2.0×	30	3.0k
Natalia Rosso Italy	23	858 0.8×	519 0.5×	365 0.6×	160 0.3×	143 0.4×	51	1.5k
Fausto Andreola United Kingdom	25	649 0.6×	861 0.9×	521 0.9×	263 0.5×	226 0.6×	55	1.9k
Jaideep Behari United States	23	1.1k 1.1×	599 0.6×	830 1.4×	328 0.6×	132 0.4×	71	2.2k
Petra Hirsova United States	28	1.9k 1.8×	1.6k 1.6×	869 1.5×	269 0.5×	728 2.0×	64	3.5k
Shannon J. McCall United States	23	1.5k 1.4×	857 0.8×	512 0.9×	667 1.2×	279 0.8×	96	3.3k
Mikihiro Tsutsumi Japan	31	1.4k 1.3×	728 0.7×	879 1.5×	273 0.5×	154 0.4×	126	2.9k

Countries citing papers authored by Rachel Beckerman

Since Specialization

Citations

This map shows the geographic impact of Rachel Beckerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Beckerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Beckerman more than expected).

Fields of papers citing papers by Rachel Beckerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Beckerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Beckerman. The network helps show where Rachel Beckerman may publish in the future.

Co-authorship network of co-authors of Rachel Beckerman

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Beckerman. A scholar is included among the top collaborators of Rachel Beckerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Beckerman. Rachel Beckerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Flerlage, Jamie E., et al.. (2024). A systematic literature review of clinical evidence and treatment burden in newly diagnosed high‐risk pediatric patients with classical Hodgkin lymphoma. Pediatric Blood & Cancer. 71(8). e31027–e31027. 1 indexed citations

Bekaii‐Saab, Tanios, Ling‐I Hsu, Muriel Siadak, et al.. (2023). Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes. The Oncologist. 28(10). 885–893. 16 indexed citations

Barnieh, Lianne, et al.. (2023). Remdesivir for Hospitalized COVID-19 Patients in the United States: Optimization of Health Care Resources. Infectious Diseases and Therapy. 12(6). 1655–1665. 3 indexed citations

Jiang, Tammy, et al.. (2023). A Critical Appraisal of Matching-Adjusted Indirect Comparisons in Spinal Muscular Atrophy. Advances in Therapy. 40(7). 2985–3005. 8 indexed citations

Beckerman, Rachel, Andrea Gori, Jakob J Malin, et al.. (2022). Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis. Scientific Reports. 12(1). 9622–9622. 20 indexed citations

Younossi, Zobair M., Atsushi Tanaka, Yuichiro Eguchi, et al.. (2018). Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. Journal of Viral Hepatitis. 25(8). 945–951. 15 indexed citations

Cacoub, P., Peter Buggisch, J.A. Carrión, et al.. (2018). Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. Journal of Viral Hepatitis. 25(7). 811–817. 22 indexed citations

Beckerman, Rachel, et al.. (2018). PND96 - FOUR-YEAR RESOURCE USE AND COSTS ASSOCIATED WITH ADMINISTRATION AND MONITORING OF DISEASE MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS. Value in Health. 21. S345–S345. 1 indexed citations

Younossi, Zobair M., et al.. (2017). In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. Liver International. 38(2). 258–265. 31 indexed citations

10.

Duttagupta, S, et al.. (2015). Regulatory Approval for Oncology Products In Brazil: A Comparison Between The Fda And Anvisa Approval Timelines. Value in Health. 18(7). A826–A826. 4 indexed citations

11.

Beckerman, Rachel, et al.. (2015). Cost-Effectiveness of Ceritinib Versus Current Therapies for Chemotherapy-Experienced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients in Mexico. Value in Health. 18(7). A821–A821. 3 indexed citations

12.

Younossi, Zobair M., Nathaniel Smith, Maria Stepanova, et al.. (2015). 228 The Impact of Sustained Viral Eradication on the Work Productivity of Patients With Chronic Hepatitis C (CHC) From the Five Western European Countries and the United States. Gastroenterology. 148(4). S–971. 1 indexed citations

13.

Beckerman, Rachel, et al.. (2014). Strategies To Overcome Hurdles In Hta Appraisals Amid Limitations Resulting From Single-Arm Trial Data. Value in Health. 17(7). A729–A729. 1 indexed citations

14.

Beckerman, Rachel, et al.. (2014). EARLY DIALOGUE WITH HEALTH TECHNOLOGY ASSESSMENT BODIES: A EUROPEAN PERSPECTIVE. International Journal of Technology Assessment in Health Care. 30(6). 571–578. 8 indexed citations

15.

Sun, Dongqi & Rachel Beckerman. (2014). Difference Between United States And Eu Authorisation Timelines And Time To Reimbursement In The Eu5. Value in Health. 17(3). A17–A17.

16.

Beckerman, Rachel & Carol Prives. (2010). Transcriptional Regulation by P53. Cold Spring Harbor Perspectives in Biology. 2(8). a000935–a000935. 461 indexed citations

17.

Ahn, Jin-Woo, Masha V. Poyurovsky, Nicole Baptiste, et al.. (2009). Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein. Cell Cycle. 8(10). 1603–1615. 24 indexed citations

18.

Karni-Schmidt, Orit, Assaf Friedler, Andrew Zupnick, et al.. (2007). Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus. Oncogene. 26(26). 3878–3891. 26 indexed citations

19.

Mycielska, Maria E., et al.. (2006). Citrate enhances in vitro metastatic behaviours of PC-3M human prostate cancer cells: Status of endogenous citrate and dependence on aconitase and fatty acid synthase. The International Journal of Biochemistry & Cell Biology. 38(10). 1766–1777. 24 indexed citations

20.

Beckerman, Rachel, et al.. (2004). Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochemical and Biophysical Research Communications. 318(4). 1072–1078. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact